Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00788944 · ClinicalTrials.gov registry record · Phase 4

Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl

A Phase 4 study of Depression, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 4
Development phase
971
Enrollment target
20
Study locations

NCT00788944 is a Phase 4 study of Depression that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 971 participants, above the 785-participant average among 679 other Depression trials with a reported enrollment target (24% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00788944, a Phase 4 study of Depression, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 4
Development phase
971 participants
Enrollment target
20
Study locations

Study Summary

This is a study to determine the percentage of patients with depression who are treated with extended-release venlafaxine HCl (U.S. marketed brand Effexor XR®) who are Poor Metabolizers (based on the levels of the drug in the blood) at 2D6 (a system in the liver that breaks down some medications and other chemicals).

Conditions Studied

Depression

Interventions

  • PROCEDURE blood draw

Study Locations (20)

California

  • Pfizer Investigational Site - National City
  • Pfizer Investigational Site - Oceanside
  • Pfizer Investigational Site - Santa Ana
  • Pfizer Investigational Site - Temecula

Florida

  • Pfizer Investigational Site - Coral Gables
  • Pfizer Investigational Site - Lauderhill
  • Pfizer Investigational Site - West Palm Beach
  • Pfizer Investigational Site - West Palm Beach

Colorado

  • Pfizer Investigational Site - Colorado Springs
  • Pfizer Investigational Site - Denver

Connecticut

  • Pfizer Investigational Site - Cromwell
  • Pfizer Investigational Site - Milford

Kansas

  • Pfizer Investigational Site - Wichita
  • Pfizer Investigational Site - Wichita

Alabama

  • Pfizer Investigational Site - Birmingham

Arizona

  • Pfizer Investigational Site - Tuscon

Arkansas

  • Pfizer Investigational Site - Little Rock

Trial Details

FieldValue
Enrollment Target 971 participants
Start Date 2008-10
Est. Completion 2009-07
Phase Phase 4

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

167 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00788944

The ClinicalTrials.gov registry entry for NCT00788944 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 971 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 785-participant average among 679 other Depression trials with a reported enrollment target (24% higher). The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which blood draw is the first listed.

NCT00788944 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Colorado.

Frequently Asked Questions

What is clinical trial NCT00788944 about?

NCT00788944 is a clinical study titled "Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl". This is a study to determine the percentage of patients with depression who are treated with extended-release venlafaxine HCl (U.S. marketed brand Effexor XR®) who are Poor Metabolizers (based on the levels of the drug in the blood) at 2D6 (a system in the liver that breaks down some medications and...

What is the current status of trial NCT00788944?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 971 participants. The study started on 2008-10. Estimated completion is 2009-07.

What conditions does trial NCT00788944 study?

This clinical trial studies the following conditions: Depression.

What interventions are being tested in trial NCT00788944?

The interventions under investigation include: blood draw (PROCEDURE).

Who is sponsoring clinical trial NCT00788944?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00788944 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Depression

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.